Press Release: European Medicines Agency recommends authorisation of novel treatment for type 2 diabetes

Author (Corporate)
Series Title
Series Details EMA/CHMP/257385/2012 (20.4.12)
Publication Date 20/04/2012
Content Type

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), on 20 April 2012, recommended the granting of a marketing authorisation for Forxiga (dapagliflozin), a novel treatment for type 2 diabetes mellitus.
Source Link http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/04/news_detail_001499.jsp&mid=WC0b01ac058004d5c1&murl=menus/news_and_events/news_and_events.jsp
Related Links
EMA: Press Release: EMA/CHMP/257385/2012 (20.4.12): European Medicines Agency recommends authorisation of novel treatment for type 2 diabetes http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2012/04/WC500125707.pdf
Subject Categories
Countries / Regions